Enliven Therapeutics (NASDAQ:ELVN) Price Target Raised to $67.00

Enliven Therapeutics (NASDAQ:ELVN) had its price objective hoisted by investment analysts at The Goldman Sachs Group from $59.00 to $67.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. The Goldman Sachs Group’s target price indicates a potential upside of 29.67% from the company’s previous close.

Other equities analysts have also issued research reports about the company. HC Wainwright increased their target price on Enliven Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a research note on Thursday, July 9th. Mizuho upped their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the company an “outperform” rating in a research note on Tuesday, June 2nd. Wall Street Zen upgraded shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, May 11th. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Friday. Finally, Stifel Nicolaus upped their target price on shares of Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Enliven Therapeutics has an average rating of “Moderate Buy” and an average price target of $70.50.

Enliven Therapeutics Price Performance

ELVN opened at $51.67 on Tuesday. The company’s 50 day simple moving average is $44.64 and its 200-day simple moving average is $36.36. The stock has a market capitalization of $3.15 billion, a P/E ratio of -30.94 and a beta of 0.24. Enliven Therapeutics has a one year low of $14.78 and a one year high of $54.10.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.38) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, analysts anticipate that Enliven Therapeutics will post -1.57 EPS for the current year.

Insider Activity

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $43.80, for a total transaction of $263,588.40. Following the sale, the chief financial officer directly owned 51,000 shares in the company, valued at approximately $2,233,800. This trade represents a 10.55% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the completion of the transaction, the director directly owned 51,884 shares in the company, valued at approximately $1,792,073.36. The trade was a 16.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 26,018 shares of company stock worth $1,113,888 in the last quarter. 3.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tema ETFs LLC boosted its stake in Enliven Therapeutics by 41.0% in the 2nd quarter. Tema ETFs LLC now owns 60,694 shares of the company’s stock worth $3,080,000 after purchasing an additional 17,638 shares during the period. Handelsbanken Fonder AB acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $878,000. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at about $126,000. Assenagon Asset Management S.A. bought a new stake in shares of Enliven Therapeutics in the second quarter valued at about $15,559,000. Finally, Seven Fleet Capital Management LP lifted its holdings in shares of Enliven Therapeutics by 159.4% in the first quarter. Seven Fleet Capital Management LP now owns 259,283 shares of the company’s stock valued at $10,164,000 after purchasing an additional 159,330 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.